TY  - JOUR 
T1  - Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice
JO  - Anais Brasileiros de Dermatologia
A1  - Mansilla-Polo, Miguel
A1  - Sahuquillo-Torralba, Antonio
A1  - Pujol-Marco, Conrad
A1  - Bargues-Navarro, Guillermo
A1  - Botella-Estrada, Rafael
SN  - 0365-0596
UL  - 10.1016/j.abd.2024.04.004
VL  - 99 
Y1  - 2024
PB  - Brasil 
ER  -